New Antimalarial Drug Leads Targeting Multiple Species And Life Cycle Stages
Funder
National Health and Medical Research Council
Funding Amount
$818,477.00
Summary
Malaria causes ~200 million clinical cases and >430,000 deaths annually. Prevention and treatment relies on drugs, however malaria parasite drug resistance is an enormous problem. To address this issue, and aim towards eliminating malaria, we need to develop new drugs. This project addresses this important health need by investigating the ability of new chemical compounds, developed at CSIRO, to kill human-infecting malaria parasites during different parts of their complicated lifecycles.
Development Of Specific Inhibitors Of Porphyromonas Gingivalis Gingipains Based On Their Cognate Propeptides
Funder
National Health and Medical Research Council
Funding Amount
$612,655.00
Summary
Gum disease (periodontitis) is an inflammatory disease caused by bacterial pathogens that is the major cause of tooth loss in adults. It is also associated with systemic diseases such as cardiovascular disease. In this study we will develop novel peptide-based therapeutics to inhibit the proteases that enable these bacteria to cause disease.
Towards Clinical Translation Of A Cell-based Therapy For Pelvic Organ Prolapse
Funder
National Health and Medical Research Council
Funding Amount
$1,100,689.00
Summary
Pelvic organ prolapse (POP) is a hidden burden affecting 50% of all women. POP is the herniation of the uterus, bladder and/or bowel into the vagina causing incontinence and sexual dysfunction. POP results from injury to pelvic tissues during childbirth. Reconstructive surgery used to treat POP often fails. We aim to develop an innovative cell-based therapy using a woman’s own mesenchymal stem cells combined with novel scaffold materials that will regenerate the damaged pelvic tissues.
A Prospective, Open-label, Single-centre/multi-site, Randomized Clinical Trial Of A Novel Maternal Microbiological “screen & Treat” Program Compared With Normal Care For The Prevention Of Preterm Birth
Funder
National Health and Medical Research Council
Funding Amount
$1,708,561.00
Summary
In 2014, our team launched the world-unique Western Australian Preterm Birth (PTB) Prevention Initiative and reduced the rate of PTB state-wide by 8%. Our next step is to trial a “screen & treat” program to detect women in mid-pregnancy at high risk of infection-driven PTB and treat them with antimicrobial medications. The study will involve more than 6000 women and aims to lower the rate of spontaneous PTB rate by 30%, which if applied nationally, may prevent 4500 PTBs each year.
Kidney failure contributes to 11% of all deaths in Australia and is projected to affect as many as 30,000 Australians by 2020, at a cumulative cost of $12 billion. Kidney transplantation is a far more effective treatment for this condition than dialysis, but there will always be a shortfall of human donors. Using pigs as donors offers a potential solution. The aim of this project is to genetically modify donor pigs so that their kidneys will not be rejected by human recipients.
A Multi Centre, Randomised, Blinded, Placebo Controlled Trial Comparing Intravenous Hydrocortisone With Placebo In Critically Ill Patients With Septic Shock.
Funder
National Health and Medical Research Council
Funding Amount
$317,997.00
Summary
This study performed across Australia and New Zealand will evaluate whether hydrocortisone, a cheap drug when administered to critically ill patients with severe infection, will save lives.
Investigating Novel Antibody Drug Conjugates For Treating Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$663,447.00
Summary
Chemotherapy is first-line treatment for advanced lung cancer patients. Most patients inevitably develop chemotherapy resistance. To increase chemotherapy effectiveness, we are developing a new antibody-based approach to target cancer cells that die because of chemotherapy. The antibody is armed with a very potent drug released specifically at the cancer to cause death of surrounding, chemotherapy-resistant cells. Killing these cells may reduce rebound cancer growth and cause an immune reaction.
Mechanism Of Action Of A Quinazolinone In Models Of PD
Funder
National Health and Medical Research Council
Funding Amount
$667,548.00
Summary
By the time symptoms of Parkinson's disease (PD) appear, 60-70% of the cells in a crucial part of the brain called the substantia nigra have been destroyed and within a few years of diagnosis, most of the remaining cells have died. This project investigates the causes of this cell loss and a how a new class of compounds could interrupts the process. Success in achieving the aims of this proposal will add to our knowledge of the causes of neuronal death in PD
Targeted LOWering Of Central Blood Pressure In Patients With Hypertension: A Randomised Controlled Trial (LOW CBP Study)
Funder
National Health and Medical Research Council
Funding Amount
$1,442,405.00
Summary
For over 100 years doctors have measured blood pressure (BP) using a cuff at the upper arm. However, this method has many drawbacks that can result in inappropriate treatment decisions. New technology has emerged to measure central BP, which allows a more accurate BP assessment and may improve patient care. This study will test the clinical value of this new measure of central BP. Findings are expected to lead to a change in the way that people with high BP are diagnosed and managed by doctors.
Determining The Tumour Suppressor Function Of The MCC Gene And Its Significance To Treatment Outcomes In Colorectal Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$620,716.00
Summary
This project analyses the early stages of bowel cancer, where we have discovered a new gene defect. We want to determine how the MCC gene defect promotes tumorigenesis and how it affects treatment outcomes, by studying a novel mouse model of bowel cancer. This will determine which cellular functions are altered following loss of MCC in bowel tumours and if the MCC defect can be exploited to identify patients who would benefit from radiotherapy or specific chemotherapies.